DKSH is revolutionizing genomic research across Southeast Asia. We have installed cutting-edge sequencing systems in Thailand and Indonesia, while propelling advanced cancer testing and groundbreaking research to new heights.
The recent analytica 2024 trade fair in Munich, Germany, emerged as a pinnacle event in the international laboratory sector. The highly anticipated tradeshow drew a crowd of over 34,000 industry professionals, featured 185 presentations, and showcased 1,066 exhibitors, including DKSH Technology.
Exclusive interview with Dr. Thidathip Wongsurawat (Dr. Tip) from Mahidol’s Siriraj Hospital, a pioneer in nanopore sequencing in Thailand and Asia.
An international research team has achieved a significant milestone by fully sequencing the human Y chromosome, the last remaining chromosome to be completely decoded. Until now, about half of the Y chromosome’s genetic information remained a mystery, largely due to limitations in available sequencing technology.
There is a growing need in molecular biology to interrogate samples for higher number of biomarkers, beyond the 2 to 5 biomarkers typically addressable with standard PCR technologies. Here, we demonstrate a novel approach to increase the level of multiplexing in digital PCR up to 15-plex by detecting each target with 2 distinct fluorophores with a 6-color digital PCR system, a method called digital PCR by color combination.
Personalized cancer diagnostics tests, known as molecular diagnostics, are genetic tests that can be performed to determine whether patients have an inherited or acquired gene mutation associated with cancer. Cancer is one of the most common forms of disease caused by gene mutations.
Asia remains a vital market for laboratory tools. Although the pandemic negatively affected sales by shutting down labs, it also benefitted certain parts of the market where demand for some research or clinical solutions skyrocketed. The laboratory tool market in Asia, excluding Japan and China, is expected to grow the fastest between 2021 and 2026.
Liquid biopsy is a useful tool during longitudinal monitoring of NSCLC patients but requires highly sensitive and reliable technologies for accurate detection of genomic alterations. Circulating tumor DNA (ctDNA) analysis has clinical utility in EGFR mutant NSCLC, while Circulating tumor cells (CTCs) consist a unique source of information at the cellular level. Digital PCR (dPCR) is a valuable tool for accurate and valid analysis of gene mutations in liquid biopsy analysis. The scope of the present study was to evaluate the presence and estimate mutation allele frequencies (MAFs) of EGFR mutations in plasma cfDNA and corresponding CTC-derived gDNA using Crystal Digital PCRâ„¢, in a group of EGFR mutant NSCLC patients under osimertinib therapy at two time points (before treatment initiation and at progression of disease).
The naica® system, a flexible digital PCR solution for assay development: application to wastewater-based epidemiology of COVID-19.
Stilla Technologies has introduced into the market the naica® system, using Crystal Digital PCR™ technology for the precise and highly sensitive quantification of nucleic acids. This powerful, yet easy-to-use digital PCR (dPCR) platform is the highest-plexing dPCR instrument available, with six fluorescent channels used to detect multiple genetic targets in a single run.
Delivering Growth – in Asia and Beyond.
© DKSH International Ltd.
Please enter your details here:
